Fundz

OncoResponse

SEATTLE, WA · Biotechnology · 12 employees

OncoResponse is a clinical stage, privately held immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of elite cancer responders. In a broad strategic alliance with MD Anderson Cancer Center, OncoResponse deploys a proprietary B-cell discovery platform to identify and develop novel therapeutics targeting the tumor microenvironment. The company’s lea

Funding history

  • Venture - Series Unknown — $6.0M — May 2025
  • Venture - Series Unknown — $13.9M — May 2023
  • Venture - Series Unknown — $40.6M — Mar 2021
  • Venture - Series Unknown — $29.5M — Mar 2017
  • Venture - Series Unknown — $16.5M — Oct 2015

Recent signals

  • May 06, 2025: Raised $6.0M in Venture - Series Unknown
  • May 12, 2023: Raised $13.9M in Venture - Series Unknown
  • Mar 31, 2021: Raised $40.6M in Venture - Series Unknown
  • Mar 23, 2017: Raised $29.5M in Venture - Series Unknown
  • Oct 15, 2015: Raised $16.5M in Venture - Series Unknown

See plans & pricing → Track OncoResponse’s funding, hiring, and signals — with verified contacts — on Fundz.